Last reviewed · How we verify
NCT03081988
Prediction Model of Response for CCRT in Esophageal Cancer
trial testing chemoradiotherapy in Esophageal Cancer in 140 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Kyungpook National University Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 140 |
| Start date | 19 October 2015 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- chemoradiotherapy — full drug profile →
Conditions studied
- Esophageal Cancer — all drugs for Esophageal Cancer →
Sponsor
Kyungpook National University Hospital
Who can join
Adults 40 to 80, any sex, with Esophageal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
1. Retrospective review of old patients * Analysis of prediction factors for concomitant chemo-radiotherapy in locally advanced and advanced esophageal cancer from 2005 to 2015 2. Prospective case-control study: RNA sequencing \& miRNA microarray * naive esophageal cancer patients who have a plan to receive concomitant chemo-radiotherapy * acquirement of tissue, blood, clinical information * isolation of RNA, DNA, serum database of clinical \& demographic information \*\*\*Analysis of mRNA sequencing / miRNA sequencing\*\*\*\* first analysis of RNA sequencing: bioinformatician second analysis of RNA sequencing: principle investigator 3. Experimental set for qPCR (esophageal tissue) study group 4. TMA for screened exon gene 5. validation set for qPCR (esophageal tissue) 6. follow-up of circulating miRNA in blood (baseline blood \& post-CCRT blood 3M, 6M, 12M) 7. Prediction model for CCRT response in esophageal Cancer based on clinical and molecular factors 8. Validate the prediction model.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
Thorel L, Perréard M, Florent R, Divoux J, et al · · 2024 · cited 90× · PMID 38945959 · DOI 10.1038/s12276-024-01272-5 -
Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update.
Bayraktar E, Bayraktar R, Oztatlici H, Lopez-Berestein G, et al · · 2023 · cited 51× · PMID 37104009 · DOI 10.3390/ncrna9020027 -
Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735 -
Patient-derived cancer models: Valuable platforms for anticancer drug testing.
Genta S, Coburn B, Cescon DW, Spreafico A. · · 2022 · cited 25× · PMID 36033445 · DOI 10.3389/fonc.2022.976065 -
Harnessing induced pluripotent stem cells and organoids for disease modeling and precision medicine.
Lee CJ, Nam Y, Rim YA, Ju JH. · · 2026 · PMID 41656303 · DOI 10.1186/s13287-026-04906-9
Verify or expand the search:
- PubMed search for NCT03081988
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of chemoradiotherapy
Trials testing the same drug.
- NCT04164797 — Study of Endostar Combined With TP Regimen for Esophageal Cancer · Phase 4 · unknown
- NCT05339763 — Long Term Bowel Function Following Rectal Cancer Surgery · NA · completed
- NCT03772756 — EUS-RFA for Unresectable Pancreatic Ductal Adenocarcinoma · NA · completed
- NCT03725254 — CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRC · Phase 2 · unknown
- NCT03680261 — Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy · Phase 3 · unknown
Other recruiting trials for Esophageal Cancer
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
Other Kyungpook National University Hospital trials
Trials by the same sponsor.
- NCT07265817 — Fecal Microbiota Transplantation for Decolonization of Multidrug-resistant Microorganisms · NA · not yet recruiting
- NCT06215040 — The Treatment Effect for Asymptomatic Common Bile Duct Stone · recruiting
- NCT05849324 — Intravascular Injection Rate During Lumbar Transforaminal Epidural Block Using Bent or Straight Needles · NA · unknown
- NCT05083026 — Neutralizing Antibody Level After COVID-19 Vaccination · unknown
- NCT05046054 — The Effect of Transcutaneous Electrical Nerve Stimulation on Pain During Propofol Injection · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03081988 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kyungpook National University Hospital
- Last refreshed: 4 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03081988.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing